Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial [Rapid Communication]

Conclusion
Adjuvant treatment that includes L did not significantly improve DFS compared with T alone and added toxicity. One year of adjuvant T remains standard of care.

Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Piccart-Gebhart, Holmes, Baselga, de Azambuja, Dueck, Viale, Zujewski, Goldhirsch, Armour, Pritchard, McCullough, Dolci, McFadden, Holmes, Tonghua, Eidtmann, Dinh, Di Cosimo, Harbeck, Tjulandin, Im, Huang, Dieras, Hillman, Wolff, Jackisch, Lang, Untch, Sm Tags: Combined Modality, Rapid Communications Source Type: research